KOMPAS.com – Indonesia has reissued AstraZeneca’s CTMAV 547 Covid-19 vaccine batch, less than two weeks after it was withdrawn from circulation on Sunday, May 16 following the death of a number of the vaccine’s recipients.
The Food and Drug Agency or BPOM cleared the batch for use on May 29, after it put the vaccine through a series of sterilization and abnormal toxicity tests at its National Center for the Development and Testing of Medicines and Foods [PPOMN].
“The tests are part of BPOM investigations to determine if there are any connections between the vaccine’s and side effects such as blood clots, fevers or headaches,” said BPOM in a press release.
“We try to determine if the distribution and storing process will affect the quality of the vaccine. The CTMAV 547 vaccine batch are shown to have normal toxicity and sterility levels, and there are no connections between the vaccine and any post immunization incidents.”
Also read: Indonesia AstraZeneca Vaccine Recipient in Bali Dies
BPOM’s findings determined that the CTMAV 547 vaccine batch, which came to Indonesia on April 26 via the Covax Facility and World Health Organization [WHO], can be used to immunize the Indonesian public.
The National Commission for Post Immunization Incidents or Komnas KIPI also ruled that Covid-19 vaccines from AstraZeneca have not killed anyone in Indonesia.
“Those who died after they received a Covid-19 vaccination did not die of the vaccine, but from other [health] factors,” said the Commission. “The AstraZeneca vaccine should continue to be distributed because it helps combat Covid-19.”
The World Health Organization [WHO] and EMA or European Medical Association review of the AstraZeneca vaccine also dispelled concerns about the vaccine causing blood clots.
“Blood clots occurred in in 222 cases out of 34 million doses [of the AstraZeneca vaccine] or 0.00065 percent,” the report said. “On the other hand, blood clots from Covid-19 occurred in 165 thousand cases out of every one million people [who were infected], or 16.5 percent.”